论文部分内容阅读
自80年代早期开展血脂干预试验后,在调整饮食改善生活方式的基础上进行冠状动脉粥样硬化性心脏病(CHD)一级及二级预防试验,一致性地证实了调整血脂不但能使CHD的发病率和死亡率下降,并且不升高非CHD的死亡率,从而可使总死亡率下降20％～30％。而国内血脂异常治疗现状调查发现,总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)的治疗达标率仅10.1％。因此,血脂异常的诊治任重道远,现将调脂药物近况综述如下。
Since the beginning of the lipid-lipid intervention trials in the early 1980s, primary and secondary prevention trials of coronary atherosclerotic heart disease (CHD) based on diet-based improvement of lifestyles have consistently demonstrated that adjusting blood lipids not only renders CHD The morbidity and mortality rates are reduced without increasing non-CHD mortality, resulting in a 20% to 30% reduction in overall mortality. However, the survey of the prevalence of dyslipidemia in China found that the treatment compliance rate of total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) was only 10.1%. Therefore, the diagnosis and treatment of dyslipidemia long way to go, the current status of lipid-lowering drugs are summarized below.